Novo Nordisk sticks to cautious obesity sales goal
![Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13097152.ece/ALTERNATES/schema-16_9/doc7gg4mt4sb6pr012np39.jpg)
Novo Nordisk is stubbornly mantaining its cautious goal for obesity sales in spite of pervasive optimism on the stock market, according to Danish media Børsen.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Eli Lilly welcomes competition for cheap insulin in US
For subscribers
Novo Nordisk wants to innovate in new ways to find cures
For subscribers